There was two-line loss of acuity in participants reporting one to 14 drinks or more a week compared with those who don't drink. They calculated that each additional drink per week increased the risk of two-line acuity loss by 2%.
While moderate drinking did not increase the risk for or progression of retinopathy in a study of more than 1,200 diabetics it nearly doubled the risk of losing two eye-chart lines of visual acuity over an average of five years.
Retinal vascular lesions by mydriatic stereoscopic photography, were no more common in diabetics who drank than in those who didn't. The study authors theorized, Alcohol is known for its neurotoxic properties, which could induce oxidative damage to the retina and the optic nerve, leading to visual loss."
FDA has approved a first-of-its-kind technology to counter a leading cause of blindness in older adults -- a tiny telescope implanted inside the eye. The Implantable Miniature Telescope aims to help in the end stages of incurable age-related macular degeneration, although the FDA warned Tuesday that patients need post-surgery rehabilitation to make it work.
Dr. Malvina Eydelman, FDA's ophthalmic devices chief, said the device can improve the quality of life for those who are 75 and older, have a certain degree of vision loss and who also need a cataract removed. In addition, the FDA took the highly unusual step of requiring that patients and their surgeons sign a detailed 'acceptance of risk agreement' before surgery, acknowledging potential side effects -- including corneal damage and worsened vision -- and the need for lots of testing to determine who's a candidate.
The benefits of the telescopic implants are numerous, such as:
1. Improving the central vision acuity of patients.
2. Can be used in combination with drugs to treat macular degeneration and photodynamic thepray. The use of anti-hypertensive and anti-angiogenic drugs to treat wet advanced macular degeneration, a condition in which ocular arteries leak inside the eye, include ranibizumab and bevabizumab which can cost upto $2,000 per treatment. Ideally, these prosthetic implants will be offered to patients who have undergone photodynamic therapy to destroy "leaky" blood vessels of the eye before this implant can be made in one eye.
3. It may be more cost effective to use these telescopic implants for the treatment of both dry and wet age related macular degeneration over time compared to the continual, protracted and expensive use of drugs. With time, the dosage and use of these drugs can be reduced once the damaged tissue is healed and the implant has been placed in one of the affected eyes.
"The telescope implant represents a new category of treatment for this severely visually impaired population," said Allen W. Hill, CEO of VisionCare.
Medscape reported that, according to a study published in the Sept. issue of the Archives of Ophthalmology, intravitreal injection of the corticosteroid triamcinolone may improve vision in retinal vein occlusion.
Researchers from the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Research Group compared "the efficacy and safety of one-mg and four-mg doses of preservative-free intravitreal triamcinolone vs. observation for eyes with vision loss associated with macular edema secondary to perfused" central retinal vein occlusion "in 271 participants." They found that the the one-mg group had five-fold greater odds of achieving the primary outcome, as "did the four-mg group," with both the "one-mg and four-mg groups" being "not significantly different from each other."
An injectable eye implant approved by the U.S. Food and Drug Administration Thursday is the first product sanctioned to treat the eye disorder macular edema when it is caused by blockage of the retinal vein.
The Ozurdex eye implant treats macular edema by delivering a high concentration of the corticosteroid dexamethasone.
Macular edema occurs when the eye's macula -- a part of the retina -- swells because of fluid accumulation from leaking or blocked retinal veins. In a news release, device maker Allergan, Inc. said retinal vein occlusion is a significant cause of vision loss and the second most common disease of the retinal veins, behind diabetic retinopathy.
The implant, which is biodegradable, was evaluated in a pair of clinical studies involving about 1,300 people.
The treatment, to be injected in a physician's office, is expected to be available later this year
Austin Village Eyecare OD PA 1013 Chestnut Lane #210 Matthews, NC 28104
About This Blog
I am an optometrist practicing in Matthews, NC – a city of 30,000 residents in the South East part of Charlotte.
My office was started in 2008. Our presence on the web is here.
We aim to provide the best possible service, eyecare and quality of goods.
Not only are we trying to grow as a business, we see ourselves as an integral part of the community we live in. I have provided free eyecare service to the Lions Club Van at the Matthews Festival, Screenings at CPCC and Charitable Health Fairs.
Our office is proud to help children of Thompson Child & Family Focus a leader in child healthcare, therapy and treatment of children with emotional and behavioral issues. In partnership with Essilor we provide free eye exams and a complete pair of spectacle lenses to these kids.
I am also a member of the Matthews Optimist Club whose purpose is to develop optimism as a philosophy of life to bring out the best in kids.